The analysis showed that ANXA2 expression was significantly higher in the bone metastatic samples when compared with the primary tumor site (p < 0.001), and no significant difference was detected for the other PCa metastatic sites (lung, liver, and lymph node) (Figure 1H). The gene discussed is ANXA2; the disease is posterior cortical atrophy.